Giusto Elena, Donegà Matteo, Cossetti Chiara, Pluchino Stefano
Dept of Clinical Neurosciences, John van Geest Centre for Brain Repair, Wellcome Trust/Medical Research Council, Stem Cell Institute, National Institute for Health Research (NIHR), Biomedical Research Centre, University of Cambridge, CB2 0PY, UK.
Exp Neurol. 2014 Oct;260:19-32. doi: 10.1016/j.expneurol.2013.03.009. Epub 2013 Mar 16.
Stem cell technology is a promising branch of regenerative medicine that is aimed at developing new approaches for the treatment of severely debilitating human diseases, including those affecting the central nervous system (CNS). Despite the increasing understanding of the mechanisms governing their biology, the application of stem cell therapeutics remains challenging. The initial idea that stem cell transplants work in vivo via the replacement of endogenous cells lost or damaged owing to disease has been challenged by accumulating evidence of their therapeutic plasticity. This new concept covers the remarkable immune regulatory and tissue trophic effects that transplanted stem cells exert at the level of the neural microenvironment to promote tissue healing via combination of immune modulatory and tissue protective actions, while retaining predominantly undifferentiated features. Among a number of promising candidate stem cell sources, neural stem/precursor cells (NPCs) are under extensive investigation with regard to their therapeutic plasticity after transplantation. The significant impact in vivo of experimental NPC therapies in animal models of inflammatory CNS diseases has raised great expectations that these stem cells, or the manipulation of the mechanisms behind their therapeutic impact, could soon be translated to human studies. This review aims to provide an update on the most recent evidence of therapeutically-relevant neuro-immune interactions following NPC transplants in animal models of multiple sclerosis, cerebral stroke and traumas of the spinal cord, and consideration of the forthcoming challenges related to the early translation of some of these exciting experimental outcomes into clinical medicines.
干细胞技术是再生医学中一个很有前景的分支,旨在开发治疗严重使人衰弱的人类疾病的新方法,包括那些影响中枢神经系统(CNS)的疾病。尽管人们对其生物学调控机制的理解不断加深,但干细胞疗法的应用仍然具有挑战性。干细胞移植在体内通过替代因疾病而丢失或受损的内源性细胞起作用这一最初观点,已受到其治疗可塑性的越来越多证据的挑战。这一新概念涵盖了移植的干细胞在神经微环境水平上发挥的显著免疫调节和组织营养作用,通过免疫调节和组织保护作用的结合促进组织愈合,同时主要保持未分化特征。在众多有前景的候选干细胞来源中,神经干/前体细胞(NPCs)在移植后的治疗可塑性方面正在接受广泛研究。实验性NPC疗法在炎症性中枢神经系统疾病动物模型中的显著体内影响,引发了人们极大的期望,即这些干细胞或对其治疗影响背后机制的操控,可能很快转化为人体研究。本综述旨在提供关于在多发性硬化症、脑卒中和脊髓损伤动物模型中NPC移植后与治疗相关的神经免疫相互作用的最新证据,并思考将其中一些令人兴奋的实验结果早期转化为临床药物所面临的挑战。